Catheter Precision Reports 60% Revenue Growth in Q4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy VTAK?
Source: seekingalpha
- Significant Revenue Growth: Catheter Precision reported Q4 revenue of $0.24 million, reflecting a robust 60% year-over-year increase, indicating strong market performance and growth potential.
- Improved Net Loss: The company recorded a net loss of $5.3 million, an improvement from $5.6 million in 2024, suggesting enhanced cost control and operational efficiency.
- Equity Transaction Completed: Creatd sold its remaining stake in Fly Flyte to Catheter Precision for approximately $12 million in cash and equity, which will strengthen the latter's market position and resource integration capabilities.
- Enhanced Financial Transparency: Catheter Precision provided detailed financial information, boosting investor confidence in the company's future prospects and offering clearer decision-making insights for potential investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTAK
About VTAK
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catheter Precision Reports 60% Revenue Growth in Q4
- Significant Revenue Growth: Catheter Precision reported Q4 revenue of $0.24 million, reflecting a robust 60% year-over-year increase, indicating strong market performance and growth potential.
- Improved Net Loss: The company recorded a net loss of $5.3 million, an improvement from $5.6 million in 2024, suggesting enhanced cost control and operational efficiency.
- Equity Transaction Completed: Creatd sold its remaining stake in Fly Flyte to Catheter Precision for approximately $12 million in cash and equity, which will strengthen the latter's market position and resource integration capabilities.
- Enhanced Financial Transparency: Catheter Precision provided detailed financial information, boosting investor confidence in the company's future prospects and offering clearer decision-making insights for potential investors.
See More
Catheter Precision Secures $88 Million Financing for Growth
- Financing Amount: Catheter Precision, Inc. announced it has secured up to $88 million in new institutional financing aimed at accelerating growth, simplifying its balance sheet, and expanding its aviation and medical device operations, reflecting strong confidence in future development.
- Aviation Expansion: The newly acquired capital will be utilized by its aviation subsidiary, Flyte, Inc., to expand its fleet, acquire additional aircraft, and enter new regional markets, thereby enhancing the company's competitiveness in the air transport sector.
- Commitment to Medical Devices: In addition to aviation, Catheter Precision reaffirmed its commitment to its cardiac arrhythmia medical device business, with the financing providing resources to strengthen both divisions and enhance its capabilities in healthcare innovation.
- Stock Split Impact: The company executed a 1-for-19 reverse stock split on August 15, 2025, and although the stock is down 14.04% in pre-market trading, it still reflects a positive market response to the financing announcement.
See More
Catheter Precision Secures $88M in Strategic Financing for Growth
- Financing Commitment: Catheter Precision (VTAK) has secured up to $88 million in strategic institutional financing commitments aimed at accelerating growth in its medical device operations, reflecting market confidence in its future prospects.
- Acquisition Completion: On Tuesday, VTAK completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, achieving full ownership of the AI-enabled regional aviation operator, which enhances its market position in the aviation sector.
- Market Reaction: Despite the financing success, VTAK's shares fell by 9.8% in premarket trading, indicating investor concerns about the company's future performance, which may impact the effectiveness of its financing plans.
- Transaction Details: Creatd (CRTDD) sold its remaining stake in Fly Flyte for approximately $12 million in cash and equity, a move that not only strengthens VTAK's asset portfolio but also provides funding support for the expansion of its aviation platform.
See More
Catheter Precision Expands Aviation Business with Fully Funded Growth Strategy
- Funding for Expansion: Catheter Precision has achieved significant balance sheet improvements through new institutional capital commitments, providing comprehensive funding support for its subsidiary Flyte's expansion strategy, enabling rapid growth in new markets.
- Growing Market Demand: Flyte's CEO Marc Sellouk noted that the demand for premium regional air travel is accelerating, positioning the company's platform to meet this demand and enhancing its market competitiveness and business potential.
- Infrastructure Development: Recent capital initiatives are expected to support the continued expansion of the Flyte platform, including fleet expansion and market development, which will simplify the balance sheet and reduce legacy liabilities, thereby enhancing operational efficiency.
- Regional Aviation Market Opportunity: As travelers prioritize time efficiency and direct routes, the regional air mobility market is viewed as a significant growth opportunity within the aviation industry, with Flyte at the forefront of this emerging sector due to its certified aircraft and active flight operations.
See More
Catheter Precision Completes 80% Acquisition of Flyte
- Acquisition Completed: Catheter Precision completed its acquisition of an 80% stake in Flyte on Tuesday, significantly increasing its market share in the rapidly growing private aviation sector, which led to a 50% surge in its stock price.
- Capital Inflow: As part of the transaction, Creatd will receive approximately $6 million in cash and $6 million in convertible preferred stock, making it a significant shareholder in VTAK and laying the groundwork for future collaboration.
- Financing Plan: Earlier this month, Catheter Precision signed a securities purchase agreement to raise about $1.9 million through a private placement, with proceeds aimed at working capital, restructuring, and reducing expenses, indicating proactive financial management.
- Market Reaction: Following the acquisition announcement, retail sentiment for VTAK on Stocktwits flipped from 'bearish' to 'extremely bullish', with investors anticipating a price increase to $3, reflecting strong market confidence in the company's future prospects.
See More
Creatd Sells Remaining Stake in Fly Flyte to Strengthen Financial Position
- Equity Sale Transaction: Creatd sold its remaining 80% stake in subsidiary Fly Flyte to Catheter Precision for approximately $6 million in cash and nearly $6 million in convertible preferred stock, significantly strengthening its financial position.
- Strategic Shareholder Status: This transaction not only improves Creatd's balance sheet but also positions it as a significant shareholder in Catheter Precision, further solidifying its investment strategy in the medical technology sector.
- Operational Optimization Background: Creatd implemented various operational and technological changes within a year of acquiring Fly Flyte, adequately preparing for this acquisition and demonstrating its capability in business integration and value enhancement.
- Ongoing Collaborative Relationship: Despite the equity transfer, Creatd and Catheter Precision will continue to collaborate through a strategic relationship focused on aviation and eVTOL logistics platform development, ensuring synergistic effects in future business growth.
See More
Catheter Precision Reports 60% Revenue Growth in Q4
- Significant Revenue Growth: Catheter Precision reported Q4 revenue of $0.24 million, reflecting a robust 60% year-over-year increase, indicating strong market performance and growth potential.
- Improved Net Loss: The company recorded a net loss of $5.3 million, an improvement from $5.6 million in 2024, suggesting enhanced cost control and operational efficiency.
- Equity Transaction Completed: Creatd sold its remaining stake in Fly Flyte to Catheter Precision for approximately $12 million in cash and equity, which will strengthen the latter's market position and resource integration capabilities.
- Enhanced Financial Transparency: Catheter Precision provided detailed financial information, boosting investor confidence in the company's future prospects and offering clearer decision-making insights for potential investors.
See More
Catheter Precision Secures $88 Million Financing for Growth
- Financing Amount: Catheter Precision, Inc. announced it has secured up to $88 million in new institutional financing aimed at accelerating growth, simplifying its balance sheet, and expanding its aviation and medical device operations, reflecting strong confidence in future development.
- Aviation Expansion: The newly acquired capital will be utilized by its aviation subsidiary, Flyte, Inc., to expand its fleet, acquire additional aircraft, and enter new regional markets, thereby enhancing the company's competitiveness in the air transport sector.
- Commitment to Medical Devices: In addition to aviation, Catheter Precision reaffirmed its commitment to its cardiac arrhythmia medical device business, with the financing providing resources to strengthen both divisions and enhance its capabilities in healthcare innovation.
- Stock Split Impact: The company executed a 1-for-19 reverse stock split on August 15, 2025, and although the stock is down 14.04% in pre-market trading, it still reflects a positive market response to the financing announcement.
See More
Catheter Precision Secures $88M in Strategic Financing for Growth
- Financing Commitment: Catheter Precision (VTAK) has secured up to $88 million in strategic institutional financing commitments aimed at accelerating growth in its medical device operations, reflecting market confidence in its future prospects.
- Acquisition Completion: On Tuesday, VTAK completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, achieving full ownership of the AI-enabled regional aviation operator, which enhances its market position in the aviation sector.
- Market Reaction: Despite the financing success, VTAK's shares fell by 9.8% in premarket trading, indicating investor concerns about the company's future performance, which may impact the effectiveness of its financing plans.
- Transaction Details: Creatd (CRTDD) sold its remaining stake in Fly Flyte for approximately $12 million in cash and equity, a move that not only strengthens VTAK's asset portfolio but also provides funding support for the expansion of its aviation platform.
See More
Catheter Precision Expands Aviation Business with Fully Funded Growth Strategy
- Funding for Expansion: Catheter Precision has achieved significant balance sheet improvements through new institutional capital commitments, providing comprehensive funding support for its subsidiary Flyte's expansion strategy, enabling rapid growth in new markets.
- Growing Market Demand: Flyte's CEO Marc Sellouk noted that the demand for premium regional air travel is accelerating, positioning the company's platform to meet this demand and enhancing its market competitiveness and business potential.
- Infrastructure Development: Recent capital initiatives are expected to support the continued expansion of the Flyte platform, including fleet expansion and market development, which will simplify the balance sheet and reduce legacy liabilities, thereby enhancing operational efficiency.
- Regional Aviation Market Opportunity: As travelers prioritize time efficiency and direct routes, the regional air mobility market is viewed as a significant growth opportunity within the aviation industry, with Flyte at the forefront of this emerging sector due to its certified aircraft and active flight operations.
See More
Catheter Precision Completes 80% Acquisition of Flyte
- Acquisition Completed: Catheter Precision completed its acquisition of an 80% stake in Flyte on Tuesday, significantly increasing its market share in the rapidly growing private aviation sector, which led to a 50% surge in its stock price.
- Capital Inflow: As part of the transaction, Creatd will receive approximately $6 million in cash and $6 million in convertible preferred stock, making it a significant shareholder in VTAK and laying the groundwork for future collaboration.
- Financing Plan: Earlier this month, Catheter Precision signed a securities purchase agreement to raise about $1.9 million through a private placement, with proceeds aimed at working capital, restructuring, and reducing expenses, indicating proactive financial management.
- Market Reaction: Following the acquisition announcement, retail sentiment for VTAK on Stocktwits flipped from 'bearish' to 'extremely bullish', with investors anticipating a price increase to $3, reflecting strong market confidence in the company's future prospects.
See More
Creatd Sells Remaining Stake in Fly Flyte to Strengthen Financial Position
- Equity Sale Transaction: Creatd sold its remaining 80% stake in subsidiary Fly Flyte to Catheter Precision for approximately $6 million in cash and nearly $6 million in convertible preferred stock, significantly strengthening its financial position.
- Strategic Shareholder Status: This transaction not only improves Creatd's balance sheet but also positions it as a significant shareholder in Catheter Precision, further solidifying its investment strategy in the medical technology sector.
- Operational Optimization Background: Creatd implemented various operational and technological changes within a year of acquiring Fly Flyte, adequately preparing for this acquisition and demonstrating its capability in business integration and value enhancement.
- Ongoing Collaborative Relationship: Despite the equity transfer, Creatd and Catheter Precision will continue to collaborate through a strategic relationship focused on aviation and eVTOL logistics platform development, ensuring synergistic effects in future business growth.
See More
